<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="939">
  <stage>Registered</stage>
  <submitdate>19/10/2005</submitdate>
  <approvaldate>19/10/2005</approvaldate>
  <nctid>NCT00242879</nctid>
  <trial_identification>
    <studytitle>A Dose Ranging Study Of GW640385 Boosted With Ritonavir (Rtv) In Comparison To A RTV-Boosted Protease Inhibitor (PI) In HIV-1 Infected PI-Experienced Adults</studytitle>
    <scientifictitle>Phase IIB, Randomized, Multicenter, Parallel Group, Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effect of Four Blinded Dosing Regimens of GW640385X/Ritonavir Compared to Open-label Current PI Therapy in HIV-1 Infected, Protease Inhibitor Experienced Adults for 2 Weeks With Long-term Assessment (&gt;48 Weeks) of Safety, Pharmacokinetic and Antiviral Activity of Selected 385/RTV Dosing Regimen(s) vs. a Ritonavir-boosted, Protease Inhibitor Containing Regimen</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>HPR20001</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Infection, Human Immunodeficiency Virus I</healthcondition>
    <healthcondition>HIV-1 Infection</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Studies of infection and infectious agents</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Sexually transmitted infections</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Acquired immune deficiency syndrome (AIDS / HIV)</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Physician determined comparator PI + ritonavir
Treatment: drugs - GW640385 + ritonavir

Treatment: drugs: Physician determined comparator PI + ritonavir


Treatment: drugs: GW640385 + ritonavir


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Time averaged change in plasma HIV-1 RNA over 16 wks</outcome>
      <timepoint />
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Proportion of subjects achieving the target pharmacokinetic (PK) GW640385 drug levels</outcome>
      <timepoint />
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Change in laboratory parameters</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Assessments of HIV viral load changes</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>GW640385 and RTV pharmacokinetic measurements</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>The incidence of adverse events</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Changes in laboratory measurements</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>ECG measurements</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>HIV viral resistance assessment</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Immunologic measures</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Inclusion criteria:

          -  18+ years of age (or =16 years of age for non-EU countries, according to local
             requirements).

          -  HIV-1 infected subjects.

          -  Females must be of either non-childbearing potential or have a negative pregnancy test
             at Screening and agree to use a protocol approved method of contraception.

          -  Plasma HIV-1 RNA (viral load) =1,000 copies/mL at Screening.

          -  Evidence of at least 2 multi-PI resistant mutations at Screening or within 3 months of
             Screening.

          -  Subjects must have been receiving the same anti-HIV medicines that they are on
             currently for at least 8 weeks prior to Screening; these anti-HIV medicines will
             include a single protease inhibitor (PI) in combination with a low dose of ritonavir
             (i.e., a ritonavir-boosted PI). However, the current PI cannot be tipranavir.

          -  Able to understand and follow protocol requirements, instructions and protocol-stated
             restrictions.

          -  Be willing and able to provide signed and dated written informed consent prior to
             study entry.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Exclusion criteria:

          -  Subjects cannot change their anti-HIV medicines between Screening and Day 1 Visit.

          -  Subjects can not be receiving dual ritonavir-boosted PIs, non-nucleoside reverse
             transcriptase inhibitors (NNRTIs) or Tipranavir at Screening.

          -  Active CDC Class C disease at screening.

          -  Pregnant or breastfeeding women.

          -  Protocol-specified laboratory abnormalities at Screening.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/08/2005</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>130</actualsamplesize>
    <recruitmentstatus>Terminated</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/06/2007</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,VIC</recruitmentstate>
    <hospital>GSK Investigational Site - Darlinghurst</hospital>
    <hospital>GSK Investigational Site - Liverpool</hospital>
    <hospital>GSK Investigational Site - South Yarra</hospital>
    <postcode>2010 - Darlinghurst</postcode>
    <postcode>2170 - Liverpool</postcode>
    <postcode>3141 - South Yarra</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arizona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Connecticut</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>District of Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Indiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kentucky</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Nevada</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>South Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Bruxelles</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>British Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Caen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>La Roche Sur Yon cedex 9</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Lyon Cedex 02</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Lyon Cedex 03</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Nantes</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris Cedex 10</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris Cedex 12</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bayern</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hessen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Nordrhein-Westfalen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hamburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Emilia-Romagna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Lombardia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Piemonte</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Puglia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Toscana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Portugal</country>
      <state>Cascais</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Portugal</country>
      <state>Lisboa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Puerto Rico</country>
      <state>Ponce</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Puerto Rico</country>
      <state>San Juan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Bucharest</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Constanta</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Iasi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>ViiV Healthcare</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a two phase study (randomised and non-randomised phase). The randomised phase will
      initially examine 4 blinded doses of GW640385 boosted with rtv (with continuation of current
      background therapy) in comparison to an ongoing, open-labeled rtv-boosted protease inhibitor
      (PI) regimen for 15 days. At the Day 15 visit, all subjects will optimize background therapy.
      Additionally, subjects receiving the lowest dose of GW640385 will be re-randomised to one of
      the higher doses and subjects in the control arm will receive a new rtv-boosted PI based on
      resistance testing at screening. Subjects will remain in the randomized phase on one of these
      4 continuing treatment arms for at least 48 weeks. An interim analysis will occur during the
      randomised phase to select for a dose of GW640385 to evaluate further in Phase III studies.
      After dose selection subjects will move to the non-randomised phase of the study. In the
      non-randomised phase subjects who are receiving GW640385 will be assigned to final selected
      dose for assessment of long term safety, tolerability, pharmacokinetics, and antiviral
      activity.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00242879</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>GSK Clinical Trials, MD</name>
      <address>GlaxoSmithKline</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>